<!DOCTYPE html>
<html lang="en">
<head>
<title>Skin Disease</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8">
<link rel="stylesheet" type="text/css" href="../../../public/css/offline.css" />
<script src="../../../public/javascripts/jquery-1.10.2.min.js"></script>
</head>
<body class="dsg-wb">

<table width="80%" class="offline">
<tr>
  <td colspan="3" class="header"><h1><a href="/">JPAC</a> <span>Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee</span></h1></td>
</tr>
<tr class="tabs">
  <td colspan="3">
              <ul>
                  <li id="64df60ce-a8e2-4c07-8729-68f41eb42fc3" class="whole-blood-and-components"><a href="../../../dsg/wb/guidelines.html"  class="active">Whole Blood and Components</a></li>
                  <li id="ddb09bf2-3dc0-4eb2-ba57-a5db69331dd1" class="geographical-disease-risk-index"><a href="../../../dsg/gdri/guidelines.html" >Geographical Disease Risk Index</a></li>
                </ul>
        </td>
</tr>
<tr>
  <td class="spacerow" colspan="3"></td>
</tr>
<tr>
  <td class="sidebar" width="25%">
    <div class="well">
          <ul class="openContentSectionWithSubs sidebarTopHeader"><li id="64df60ce-a8e2-4c07-8729-68f41eb42fc3" class="whole-blood-and-components sectionHead first last"><a href="../../../dsg/wb.html">Whole Blood and Components</a>
<ul class="">
<li id="42be2de8-89aa-4908-8bc8-702f9e636a81" class="a-z-search active first"><a href="../../../dsg/wb/guidelines.html">A-Z Search</a>
</li><li id="1f7e1f13-8b29-4772-ae9d-2b5cc3d59491" class="updates"><a href="../../../dsg/wb/latest-updates.html">Updates</a>
</li><li id="f83d68fb-19de-4588-9a36-a8bba0aa6494" class="drug-index"><a href="../../../dsg/wb/drug-index.html">Drug Index</a>

</li><li id="769da873-1c35-4600-8be8-d2df902570a0" class="preliminaries"><a href="../../../dsg/wb/preliminaries.html">Preliminaries</a>
<ul class="">
<li id="258895c3-f3dd-45c6-932c-3fe4795870c2" class="introduction first"><a href="../../../dsg/wb/preliminaries/introduction.html">Introduction</a>
</li><li id="ef298454-8327-4f6c-9f4a-835e437df103" class="document-and-change-control"><a href="../../../dsg/wb/preliminaries/document-and-change-control.html">Document and Change Control</a>
</li><li id="093e6463-a089-49dd-9199-c8f92559f486" class="general-principles"><a href="../../../dsg/wb/preliminaries/general-principles.html">General Principles</a>
</li><li id="96f75c3a-2c62-445b-847c-353098eaec1e" class="medication"><a href="../../../dsg/wb/preliminaries/medication.html">Medication</a>
</li><li id="ed51942d-a7fd-42f7-8269-d23b879f99ca" class="inspection-of-the-donor"><a href="../../../dsg/wb/preliminaries/inspection-of-the-donor.html">Inspection of the Donor</a>
</li><li id="99af8b5e-491b-4d67-b69a-812d81af4d7d" class="use-of-alphabetical-listing last"><a href="../../../dsg/wb/preliminaries/use-of-alphabetical-listing.html">Use of Alphabetical Listing</a>
</li></ul>
</li><li id="753eb36f-2636-414c-84ee-1004e197502d" class="appendices"><a href="../../../dsg/wb/appendicies.html">Appendices</a>
<ul class="">
<li id="e147bd96-a025-4ffa-b530-b9abefc27043" class="appendix-1---estimated-blood-volume-for-female-donors-after-nadler--by-height-and-weight first"><a href="../../../dsg/wb/appendicies/appendix-1.html">Appendix 1 - Estimated Blood Volume for Female donors (after Nadler)  by height and weight</a>
</li><li id="2f1eca54-e34f-4ece-90a4-7dfe0f210c8d" class="appendix-2---table-of-immunisations-"><a href="../../../dsg/wb/appendicies/appendix-2-table-of-immunizations.html">Appendix 2 - Table of Immunisations </a>
</li><li id="a27f8ce9-b4f6-4a9b-baf0-6f655955a9aa" class="appendix-3---maximum-permitted-ecv-for-component-donors"><a href="../../../dsg/wb/appendicies/appendix-3-maximum-permitted-extra-corporeal-volume-for-component-donors.html">Appendix 3 - Maximum permitted ECV for component donors</a>
</li><li id="90c869cb-7256-4604-8699-d8a86f78aa26" class="appendix-4---management-of-post-donation-illness last"><a href="../../../dsg/wb/appendicies/appendix-4-management-of-post-donation-illness.html">Appendix 4 - Management of post donation illness</a>
</li></ul>
</li><li id="b62a2d12-6d94-4106-92a8-1de426a4b863" class="source-files last"><a href="../../../dsg/wb/source-files.html">Source Files</a>
</li></ul>
</li></ul>
    </div>
  </td>
  <td width="5%"></td>
  <td width="70%" class="content">
    <h2>Skin Disease</h2>    

<table class="data-table"><tbody><tr class="data-row"><td class="data-label">Obligatory</td><td class="data-value"><p><b>Must not donate if:</b><br />
a) The donor has a condition that is infected or infectious e.g. Scabies.<br />
<br />
b) History of malignancy.<br />
<br />
c) The venepuncture site is affected.<br />
<br />
d) Required application of steroid, tacrolimus (Protopic<sup>&reg;</sup>) or pimecrolimus (Elidel<sup>&reg;</sup>) creams over large areas for periods of more than three weeks in the last six months.<br />
<br />
e) Ever been treated with Etretinate (Tigason<sup>&reg;</sup>).<br />
<br />
f) Less than 36 months from the last dose of acitretin (Neotigason<sup>&reg;</sup>).<br />
<br />
g) Less than four weeks from the last does of isotretinoin (Roaccutane<sup>&reg;</sup>) or Alitretinoin (Toctino<sup>&reg;</sup>).<br />
<br />
h) Has any current open skin wounds or infection.</p></td></tr><tr class="data-row"><td class="data-label">Discretionary</td><td class="data-value"><p>a) If occasional use of steroid, tacrolimus (Protopic<sup>&reg;</sup>) or pimecrolimus (Elidel<sup>&reg;</sup>) or other creams over small areas of skin and none of the above apply, accept.<br />
<br />
b) If chronic superficial fungal infection (e.g. ringworm, athlete's foot, chronic fungal nail infection or tinea) on local therapy only or has been in contact with an infected individual, accept.<br />
<br />
c) If in contact with scabies but not obviously infected, accept.<br />
<br />
d) If malignancy was a basal cell carcinoma (rodent ulcer) and treatment is completed and all wounds healed, accept.<br />
<br />
<b>For donors with Lichen Sclerosus requiring treatment other than topical steroid therapy only, excluding Etretinate (Tigason<sup>&reg;</sup>):</b><br />
e) If more than 24 months from completing treatment, have no areas of open wound or infection, have no history of associated malignancy and symptoms are controlled with or without intermittent use of topical steroid therapy only, accept.</p></td></tr><tr class="data-row"><td class="data-label">See</td><td class="data-value"><p>Is there is a specific A-Z index entry for the treatment and/or condition you are concerned about?</p></td></tr><tr class="data-row"><td class="data-label">See if Relevant</td><td class="data-value"><p><a href="../../../dsg/wb/guidelines/ac007-acne.html">Acne</a><br />
<a href="../../../dsg/wb/guidelines/an001-anaemia.html">Anaemia</a><br />
<a href="../../../dsg/wb/guidelines/au001-autoimmune-disease.html">Autoimmune disease</a><br />
<a href="../../../dsg/wb/guidelines/de011-dermatitis.html">Dermatitis</a><br />
<a href="../../../dsg/wb/guidelines/he025-herpes-simplex.html">Herpes Simplex</a><br />
<a href="../../../dsg/wb/guidelines/im005-immunosuppression.html">Immunodeficiency</a><br />
<a href="../../../dsg/wb/guidelines/in005-infection-general.html">Infection - General</a><br />
<a href="../../../dsg/wb/guidelines/ma006-malignancy.html">Malignancy</a><br />
<a href="../../../dsg/wb/guidelines/ps001-psoriasis.html">Psoriasis</a><br />
<a href="../../../dsg/wb/guidelines/st003-steroid-therapy.html">Steroid Therapy</a><br />
<a href="../../../dsg/wb/guidelines/su002-surgery.html">Surgery</a><br />
<a href="../../../dsg/wb/guidelines/th008-thrush.html">Thrush</a><br />
<a href="../../../dsg/wb/guidelines/th011-thyroid-disease.html">Thyroid disease</a><br />
<a href="../../../dsg/wb/guidelines/wo001-wounds-mouth-and-skin-ulcers.html">Wounds, Mouth and Skin Ulcers</a></p></td></tr><tr class="data-row"><td class="data-label">Additional Information</td><td class="data-value"><p>A donor who has been in contact with scabies but has no symptoms (e.g. itching) does not pose a risk to other donors or staff.<br />
<br />
Damaged skin can increase the risk of infection contaminating a donation. For this reason a venepuncture should not be performed through an area of affected skin.<br />
<br />
Many malignancies spread through the blood stream. It is therefore considered safer not to accept donations of blood from people who have been diagnosed with malignancy. Treated basal cell carcinoma is an exception to this as it is not spread through the blood stream.<br />
<br />
Initial treatment of Lichen Sclerosus is through specialist care with potent steroid therapies.<br />
<br />
Treatment can also be with methotrexate and retinoids such as Etretinate (Tigason<sup>&reg;</sup>) or acitretin (Neotigason<sup>&reg;</sup>). If taken systemically these can cause birth defects for babies exposed to them before birth. It is important to allow time for the drug to be cleared from the blood of a donor. Some drugs take longer to be cleared than others.<br />
<br />
Under normal circumstances the use of topical treatment with steroid, tacrolimus and pimecrolimus will not result in blood levels which cause suppression of the adrenal system or immune response. Side effects are more likely if there is a skin barrier defect or high doses are used over large areas for extended periods. A large area of skin is defined as &gt;9% (Wallace Rule of Nines). 1% is equal to the area of the closed digits and palm of the donor's hand.</p></td></tr><tr class="data-row"><td class="data-label">Reason for change</td><td class="data-value"><p>Link updated from 'Immunosuppression' to 'Immunodeficiency' in the 'See if Relevant' section.</p></td></tr><tr class="data-row"><td class="data-label">Donor Information</td><td class="data-value"><p>If you wish to obtain more information regarding a personal medical issue, please contact your <a href="../../../dsg/wb/guidelines/nn099-national-help-lines.html">National Help Line</a>.<br />
<br />
Please do not contact this web site for personal medical queries, as we are not in a position to provide individual answers.</p></td></tr></tbody></table>
<div class="pull-right attachments"><div class="cms images">
  
</div></div>

  
<dl class="update-information"><dt class="data-label"><h4>Update Information</h4></dt><dd class="data-value"><p>This entry was last updated in:<br />
WB-DSG&nbsp;Edition 203&nbsp;Release 73</p></dd></dl>  </td>
</tr>
</table>
</body>
</html>